High preoperative serum sVCAM-1 concentration as a predictor of early ovarian cancer recurrence

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer

“…In addition to being associated with the progression of several immunological diseases such as rheumatoid arthritis and asthma [ 29 ], there has recently been increasing evidence that elevated serum or plasma soluble VCAM-1 (sVCAM-1) levels are also associated with the progression of various cancers such as breast [ 30 , 31 ], ovarian [ 31 ], gastric [ 31 – 34 ], colorectal [ 35 , 36 ], bladder cancers [ 31 , 37 , 38 ], prostate [ 39 ], leukemia [ 40 ], and myeloma [ 41 ], suggesting VCAM-1 as a potential therapeutic target in immunological diseases and cancer [ 29 , 42 ]. Circulating levels of sVCAM-1 have been identified as a predictive biomarker for overall survival and postoperative recurrence in ovarian, prostate and colorectal cancer patients [ 8 , 39 , 43 , 44 ]. Slack-Davis et al reported that VCAM-1 interacts with its ligand α4β1 integrin and is involved in the regulation of mesothelial invasion and metastatic progression of ovarian cancer cells [ 45 ].…”

“…Using VCAM-1-specific imaging probes, VCAM-1 expression was identified as a potential marker of ovarian cancer peritoneal metastasis and therapeutic response to platinum-based agents [ 46 ]. In addition, VCAM-1 expression correlated with tumorigenesis and poor prognosis in ovarian cancer [ 47 , 48 ], and higher preoperative serum sVCAM-1 concentrations in ovarian cancer patients were linked to early tumor recurrence or disease progression [ 8 ]. In our study, serum VCAM-1 levels were found to be significantly elevated in ovarian cancer (as well as recurrent tumors) when compared to healthy controls.…”